Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

Two Dearborn County high school seniors recently learned they are the 2025 recipients of a prestigious Lilly Endowment ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

U.S. stocks rose to turn what would have been one of the market’s worst weeks of the year into just a pretty bad one ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep ...

Eli Lilly said the Food and Drug Administration approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity.

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...